
Veronica P. Hoke
Examiner (ID: 11195)
| Most Active Art Unit | 1503 |
| Art Unit(s) | 1509, 1714, 4714, 1503, 1511 |
| Total Applications | 2163 |
| Issued Applications | 1671 |
| Pending Applications | 44 |
| Abandoned Applications | 448 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16977627
[patent_doc_number] => 20210221864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => MASKED CYTOKINE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/270795
[patent_app_country] => US
[patent_app_date] => 2019-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270795
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/270795 | MASKED CYTOKINE CONJUGATES | Aug 22, 2019 | Pending |
Array
(
[id] => 15239647
[patent_doc_number] => 20190374609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
[patent_app_type] => utility
[patent_app_number] => 16/542135
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542135
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/542135 | COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1 | Aug 14, 2019 | Abandoned |
Array
(
[id] => 15035667
[patent_doc_number] => 20190328838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => COMPOSITIONS COMPRISING IL-2 FUSION PROTEINS AND METHODS FOR TREATING NEOPLASIA
[patent_app_type] => utility
[patent_app_number] => 16/510835
[patent_app_country] => US
[patent_app_date] => 2019-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29843
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510835
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/510835 | COMPOSITIONS COMPRISING IL-2 FUSION PROTEINS AND METHODS FOR TREATING NEOPLASIA | Jul 11, 2019 | Abandoned |
Array
(
[id] => 15038651
[patent_doc_number] => 20190330330
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ANTAGONISM OF THE IL-20R
[patent_app_type] => utility
[patent_app_number] => 16/507126
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10775
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507126
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/507126 | Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R | Jul 9, 2019 | Issued |
Array
(
[id] => 15360881
[patent_doc_number] => 20200016205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => Suppression of Microglial Activation with Innate Lymphoid Cells
[patent_app_type] => utility
[patent_app_number] => 16/451426
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451426
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/451426 | Suppression of Microglial Activation with Innate Lymphoid Cells | Jun 24, 2019 | Abandoned |
Array
(
[id] => 19550943
[patent_doc_number] => 12134639
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => IL-15Ra sushi domain--IL-15 fusion proteins
[patent_app_type] => utility
[patent_app_number] => 16/440779
[patent_app_country] => US
[patent_app_date] => 2019-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 42
[patent_no_of_words] => 23566
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440779
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/440779 | IL-15Ra sushi domain--IL-15 fusion proteins | Jun 12, 2019 | Issued |
Array
(
[id] => 14960805
[patent_doc_number] => 20190307880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-10
[patent_title] => METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/439423
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39074
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439423
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/439423 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | Jun 11, 2019 | Abandoned |
Array
(
[id] => 15454495
[patent_doc_number] => 20200040072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => METHODS OF TREATMENT USING IL-23p19 MONOCLONAL ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/435960
[patent_app_country] => US
[patent_app_date] => 2019-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435960
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/435960 | Methods of treatment using IL-23p19 monoclonal antibodies | Jun 9, 2019 | Issued |
Array
(
[id] => 17036713
[patent_doc_number] => 20210253671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => Pharmaceutical Composition Containing Fusion Protein and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 16/972646
[patent_app_country] => US
[patent_app_date] => 2019-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22419
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972646
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/972646 | Pharmaceutical Composition Containing Fusion Protein and Use Thereof | Jun 6, 2019 | Abandoned |
Array
(
[id] => 18801320
[patent_doc_number] => 11834472
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/972357
[patent_app_country] => US
[patent_app_date] => 2019-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 25
[patent_no_of_words] => 29818
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972357
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/972357 | Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof | Jun 3, 2019 | Issued |
Array
(
[id] => 14808357
[patent_doc_number] => 20190270788
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 16/415143
[patent_app_country] => US
[patent_app_date] => 2019-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16415143
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/415143 | CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS | May 16, 2019 | Abandoned |
Array
(
[id] => 16761071
[patent_doc_number] => 20210106652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
[patent_app_type] => utility
[patent_app_number] => 17/043197
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/043197 | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation | Apr 10, 2019 | Abandoned |
Array
(
[id] => 16870107
[patent_doc_number] => 20210163574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => SYNTHETIC SIGNALING CONSTRUCTS AND ITS USE
[patent_app_type] => utility
[patent_app_number] => 17/045363
[patent_app_country] => US
[patent_app_date] => 2019-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045363
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/045363 | SYNTHETIC SIGNALING CONSTRUCTS AND ITS USE | Apr 7, 2019 | Pending |
Array
(
[id] => 16711940
[patent_doc_number] => 20210079087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS USING ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A)
[patent_app_type] => utility
[patent_app_number] => 17/046220
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046220
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046220 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS USING ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A) | Mar 28, 2019 | Abandoned |
Array
(
[id] => 16613672
[patent_doc_number] => 20210032325
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => METHODS OF TREATING ULCERATIVE COLITIS
[patent_app_type] => utility
[patent_app_number] => 16/981915
[patent_app_country] => US
[patent_app_date] => 2019-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981915
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/981915 | Methods of treating ulcerative colitis with an anti-IL-23p19 antibody | Mar 27, 2019 | Issued |
Array
(
[id] => 14534625
[patent_doc_number] => 20190202934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => TARGETED MODIFIED IL-1 FAMILY MEMBERS
[patent_app_type] => utility
[patent_app_number] => 16/360793
[patent_app_country] => US
[patent_app_date] => 2019-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360793
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/360793 | TARGETED MODIFIED IL-1 FAMILY MEMBERS | Mar 20, 2019 | Abandoned |
Array
(
[id] => 14531745
[patent_doc_number] => 20190201493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => METHODS OF TUMOUR THERAPY WITH A COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/357756
[patent_app_country] => US
[patent_app_date] => 2019-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357756
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/357756 | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody | Mar 18, 2019 | Issued |
Array
(
[id] => 14808387
[patent_doc_number] => 20190270803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 16/356309
[patent_app_country] => US
[patent_app_date] => 2019-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356309
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/356309 | Uses of IL-13 antagonists for treating atopic dermatitis | Mar 17, 2019 | Issued |
Array
(
[id] => 19291602
[patent_doc_number] => 12030949
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-09
[patent_title] => Multispecific antibodies against IL-5 and IL-4R
[patent_app_type] => utility
[patent_app_number] => 16/966237
[patent_app_country] => US
[patent_app_date] => 2019-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 27
[patent_no_of_words] => 31315
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966237
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/966237 | Multispecific antibodies against IL-5 and IL-4R | Feb 14, 2019 | Issued |
Array
(
[id] => 15496285
[patent_doc_number] => 20200048331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => IMMUNOREGULATORY STRUCTURES FROM NORMALLY OCCURING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/272876
[patent_app_country] => US
[patent_app_date] => 2019-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272876
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/272876 | IMMUNOREGULATORY STRUCTURES FROM NORMALLY OCCURING PROTEINS | Feb 10, 2019 | Abandoned |